



Wyeth announces the winners of its first award for research into the causes of psoriasis and TNF-related skin disorders

18 September 2008

Maidenhead, UK: Wyeth Pharmaceuticals is pleased to announce the names of the six winners of its *Advances in Psoriasis Research Grant* programme who will each receive 100,000 Euros. The programme was set up to recognise and reward the endeavours of research scientists in investigating the causes and effects of inflammatory diseases such as psoriasis and other skin disorders.

The entry criteria tasked researchers to submit an outline of a high quality, innovative project that would explore the inflammatory pathogenesis of psoriasis and other disorders related to tumour necrosis factor (TNF). The applications had to show feasibility within the budget and timeframe, be compliant with local and national guidelines and be supported by a robust scientific rationale. The scheme was open to researchers resident in Europe, the Middle East and Africa who were either lab-based or clinical.

The winners are:

Professor Wolf Henning Boehncke, Johann Wolfgang Goethe University, Frankfurt, Germany
Influence on insulin resistance and co-morbidities by systemic anti-psoriatic therapies

Dr Antonio Constanzo, University of Rome Tor Vergata, Rome, Italy

Anti-inflammatory activity of IKK- α in psoriasis: cross-talk between the TNF- α and the TGF- β pathways

Associate Professor Lars Iversen, Aarhus University Hospital, Aarhus, Denmark

Inflammatory caspases, inflammasomes, and MAPK phosphatases in the pathogenesis of psoriasis

Professor Frank Nestle, King's College London, United Kingdom

Investigation of the functional role of the interleukin-23 receptor gene variant in the immunopathogenesis of psoriasis

Professor Joost Schalkwijk, Radboud University Medical Centre, Nijmegen, Netherlands

The role of β -defensins in psoriasis

Professor Mona Stahle, Karolinska University Hospital, Stockholm, Sweden

Genetic variation and microRNA-mediated regulation of genes in the TNF- α pathway in psoriasis

The winners were chosen from a highly competitive field of over 50 applications by a panel of experts drawn from international leaders in dermatology and chaired by Professor Jörg Prinz from the Department of Dermatology at the Ludwig-Maximilians University in Munich, Germany. Congratulating the winners Professor Prinz said: "All of the winners should be very proud as their work is vitally important in advancing research into psoriasis. It helps us understand the condition and in the long run it will improve how clinicians treat patients and help improve results. This has a direct bearing on improving treatment outcomes and in improving quality of life for patients. I would also like to thank Wyeth for their continued commitment to helping scientists continue this type of research."

- ends -

For further information, please contact:

Wyeth:

Gill Markham, Communications – Europe, Middle East and Africa

Direct Tel: +44 (0)1628 692536

Email: markhagl@wyeth.com

Danielle Halstrom, Communications – Global

Mobile: +1 215 280 3898

Email: halstrd@wyeth.com

OgilvyHealthPR:

Nerea Hinzpeter

Tel: +1 646 407 9015

Email: nerea.hinzpeter@ohpr.com

Christina Mavroleon

Tel: + 44 207 108 6069

Email: Christina.mavroleon@ohpr.com

To access further media information relating to this press release, additional information on Enbrel and future media announcements, please log on to the media centre at www.wyeth.eu.

Notes to editors

ABOUT WYETH:

Wyeth Pharmaceuticals, a division of Wyeth, has leading products in the areas of women's health care, infectious disease, gastrointestinal health, central nervous system, inflammation, transplantation, hemophilia, oncology, vaccines and nutritional products.

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

ABOUT THE ADVANCES IN PSORIASIS AWARDS

For further information please visit: www.advancesinpsoriasis.com